AstraZeneca and MedImmune, its global biologics research and development arm, will present 54 abstracts, including eight oral presentations and three late breakers, to the European Society of Medical Oncology (ESMO 2018) Congress in Munich, Germany, 19-23 October.
Ook interessant voor je
AstraZeneca’s Tagrisso approved by FDA for lung cancer treatment
Tagrisso approved by FDA for lung cancer treatment The approval followed a Priority Review by the FDA and was based on results from the FLAURA2 phase 3 trial, which were published in The New England Journal of Medicine...
11 x gelezen
FDA Drug Approval Decisions Expected in February 2024
FDA Drug Approval Decisions Expected in February 2024 The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or...
FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment
FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) has approved Keytruda...
5 x gelezen
Reageer